Hepatopulmonary syndrome and portopulmonary hypertension in the model for end-stage liver disease (MELD) era.
1. How do physicians decide which patients with pulmonary vascular disease will benefit from liver transplantation? 2. Studies on patients with pulmonary vascular disease are limited and the findings and recommendations may not apply to all practice sites. 3. All patients with hypoxemia, liver disease, and pulmonary vasodilation do not have hepatopulmonary syndrome (HPS). 4. Not all patients with hepatopulmonary syndrome will benefit from liver transplantation. 5. The mean pulmonary artery pressure (mPAP) may not be an accurate predictor of mortality in patients with portopulmonary hypertension. 6. The effects of pulmonary vasodilators on the outcome of patients with portopulmonary hypertension (PPHTN) is still unconfirmed but promising.
Mandell
M Susan
MS
Department of Anesthesiology, University of Colorado Health Sciences, Denver, CO, USA. susan.mandell@uchsc.edu
D003661:Decision Support Techniques; D003937:Diagnosis, Differential; D020065:Hepatopulmonary Syndrome / Q000503:physiopathology / Q000601:surgery*; D006801:Humans; D006975:Hypertension, Portal / Q000150:complications* / Q000503:physiopathology / Q000601:surgery*; D006976:Hypertension, Pulmonary / Q000150:complications* / Q000503:physiopathology / Q000601:surgery*; D017093:Liver Failure / Q000503:physiopathology; D016031:Liver Transplantation / Q000401:mortality; D015233:Models, Statistical; D011379:Prognosis